JP2010522698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522698A5 JP2010522698A5 JP2010500036A JP2010500036A JP2010522698A5 JP 2010522698 A5 JP2010522698 A5 JP 2010522698A5 JP 2010500036 A JP2010500036 A JP 2010500036A JP 2010500036 A JP2010500036 A JP 2010500036A JP 2010522698 A5 JP2010522698 A5 JP 2010522698A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- methionine
- weight percent
- miu
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 35
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 22
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 22
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 18
- 229960004452 methionine Drugs 0.000 claims description 15
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 13
- 229930195722 L-methionine Natural products 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 9
- 239000007764 o/w emulsion Substances 0.000 claims description 9
- 206010008263 Cervical dysplasia Diseases 0.000 claims description 5
- 239000000232 Lipid Bilayer Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 230000002051 biphasic effect Effects 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90932407P | 2007-03-30 | 2007-03-30 | |
| US60/909,324 | 2007-03-30 | ||
| PCT/CA2008/000563 WO2008119160A1 (en) | 2007-03-30 | 2008-03-27 | Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010522698A JP2010522698A (ja) | 2010-07-08 |
| JP2010522698A5 true JP2010522698A5 (enExample) | 2011-05-19 |
| JP5587762B2 JP5587762B2 (ja) | 2014-09-10 |
Family
ID=39807744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010500036A Expired - Fee Related JP5587762B2 (ja) | 2007-03-30 | 2008-03-27 | 膣内送達により子宮頸部異形成を治療するための二相性脂質小胞組成物および方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8945529B2 (enExample) |
| EP (1) | EP2134353B1 (enExample) |
| JP (1) | JP5587762B2 (enExample) |
| KR (1) | KR20090130081A (enExample) |
| AU (1) | AU2008234364B2 (enExample) |
| CA (1) | CA2681565C (enExample) |
| CY (1) | CY1118794T1 (enExample) |
| DK (1) | DK2134353T3 (enExample) |
| ES (1) | ES2617063T3 (enExample) |
| HR (1) | HRP20170250T1 (enExample) |
| HU (1) | HUE033256T2 (enExample) |
| LT (1) | LT2134353T (enExample) |
| MX (1) | MX2009010405A (enExample) |
| PL (1) | PL2134353T3 (enExample) |
| PT (1) | PT2134353T (enExample) |
| SI (1) | SI2134353T1 (enExample) |
| TW (1) | TWI440477B (enExample) |
| WO (1) | WO2008119160A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008900B1 (fr) * | 2013-07-25 | 2018-03-30 | Centre Nat Rech Scient | Nanoparticules lipidiques multicompartimentees |
| US8986732B2 (en) * | 2013-08-12 | 2015-03-24 | Helix Biopharma Corporation | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| US10159646B2 (en) | 2013-08-12 | 2018-12-25 | Altum-Avro Pharma Partnership | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US20150147382A1 (en) * | 2013-09-23 | 2015-05-28 | Exir Nano Sina Company | Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same |
| ES2952779T3 (es) | 2017-05-18 | 2023-11-06 | Modernatx Inc | ARN mensajero modificado que comprende elementos de ARN funcionales |
| EP3630067A4 (en) * | 2017-05-26 | 2021-08-11 | Altum Pharmaceuticals Inc. | GIVING A BIPHASIC CANNABINOID |
| EP3714048B1 (en) | 2017-11-22 | 2025-04-09 | ModernaTX, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
| WO2019104160A2 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
| EP3849595B1 (en) | 2018-09-13 | 2025-11-19 | ModernaTX, Inc. | Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease |
| US20220401584A1 (en) | 2018-09-14 | 2022-12-22 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| KR20220070246A (ko) | 2019-09-23 | 2022-05-30 | 디디에스 리서치 인크. | 침투 증진제를 갖는 지질 소포 조성물 |
| WO2022204380A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
| WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
| WO2022204371A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
| MX2023011157A (es) | 2021-03-24 | 2024-01-25 | Glo Pharma Inc | Peptidos y metodos para reducir la pigmentacion de la piel. |
| US20240376445A1 (en) | 2021-06-22 | 2024-11-14 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| KR20240102989A (ko) * | 2021-11-04 | 2024-07-03 | 글로 파마, 인크. | 화장품 적용을 위한 방법 및 조성물 |
| MA71619A (fr) | 2022-07-26 | 2025-05-30 | Modernatx, Inc. | Polynucléotides modifiés pour la régulation temporelle de l'expression |
| WO2024130158A1 (en) | 2022-12-16 | 2024-06-20 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
| CA2168260C (en) | 1993-07-28 | 2000-04-11 | Marianna Foldvari | Biphasic multilamellar lipid vesicles |
| IN184589B (enExample) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| US5993852A (en) * | 1997-08-29 | 1999-11-30 | Pharmaderm Laboratories Ltd. | Biphasic lipid vesicle composition for transdermal administration of an immunogen |
| US6656499B1 (en) * | 1999-11-12 | 2003-12-02 | Pharmaderm Laboratories, Ltd. | Composition for transdermal and dermal administration of interferon-α |
| TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
| EP1576952A1 (en) | 2004-03-18 | 2005-09-21 | OctoPlus Technologies B.V. | Hydrogel microspheres with improved release profile |
-
2008
- 2008-03-27 EP EP08733666.5A patent/EP2134353B1/en active Active
- 2008-03-27 JP JP2010500036A patent/JP5587762B2/ja not_active Expired - Fee Related
- 2008-03-27 CA CA2681565A patent/CA2681565C/en active Active
- 2008-03-27 PL PL08733666T patent/PL2134353T3/pl unknown
- 2008-03-27 LT LTEP08733666.5T patent/LT2134353T/lt unknown
- 2008-03-27 SI SI200831765A patent/SI2134353T1/sl unknown
- 2008-03-27 HU HUE08733666A patent/HUE033256T2/hu unknown
- 2008-03-27 WO PCT/CA2008/000563 patent/WO2008119160A1/en not_active Ceased
- 2008-03-27 MX MX2009010405A patent/MX2009010405A/es active IP Right Grant
- 2008-03-27 AU AU2008234364A patent/AU2008234364B2/en not_active Ceased
- 2008-03-27 KR KR1020097022186A patent/KR20090130081A/ko not_active Ceased
- 2008-03-27 HR HRP20170250TT patent/HRP20170250T1/hr unknown
- 2008-03-27 ES ES08733666.5T patent/ES2617063T3/es active Active
- 2008-03-27 DK DK08733666.5T patent/DK2134353T3/en active
- 2008-03-27 PT PT87336665T patent/PT2134353T/pt unknown
- 2008-03-27 US US12/532,752 patent/US8945529B2/en active Active
- 2008-03-28 TW TW097111592A patent/TWI440477B/zh not_active IP Right Cessation
-
2013
- 2013-03-22 US US13/849,451 patent/US20130216610A1/en not_active Abandoned
- 2013-03-22 US US13/849,455 patent/US20130224283A1/en not_active Abandoned
-
2017
- 2017-02-14 CY CY20171100200T patent/CY1118794T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009010405A (es) | Composicion en vesicula de lipido bifasico y metodo para tratar la displasia cervical mediante suministro intravaginal. | |
| JP2021066744A5 (ja) | ブプロピオンおよびデキストロメトルファンを含む組成物 | |
| US20200222544A1 (en) | Linear polysaccharide based film products | |
| EP4678164A3 (en) | Cationic lipids for use in lipid nanoparticles | |
| JP2013515009A5 (enExample) | ||
| JP2009507838A5 (enExample) | ||
| EP1537859A3 (en) | Azithromycin dosage forms with reduced side effects | |
| JP2003506416A5 (enExample) | ||
| AP1760A (en) | Platinum derivative pharmaceutical formulations. | |
| MXPA05010565A (es) | Sistemas de suminsitro de farmacos que comprenden un ingrediente activo encapsulado. | |
| CN109952101A (zh) | 治疗高细胞因子血症和病毒感染的肥大细胞稳定剂 | |
| JP2011225596A5 (enExample) | ||
| JP2019508437A (ja) | モンテルカスト経粘膜フィルム | |
| JP2013516493A5 (enExample) | ||
| JP2013535472A5 (enExample) | ||
| JP2023517920A5 (enExample) | ||
| JP2017514911A5 (enExample) | ||
| SI1561460T1 (sl) | Nanodelci za aplikacijo uäśinkovin, postopek za pripravo teh delcev in sestavek, ki jih vsebuje | |
| KR20140121394A (ko) | 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 | |
| JP2018529747A5 (enExample) | ||
| JP2012526099A5 (enExample) | ||
| HRP20180327T1 (hr) | Sredstva za uporabu u slučaju intolerancije na fruktozu | |
| JP2011157395A5 (enExample) | ||
| WO2006026095A3 (en) | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid | |
| RU2002116377A (ru) | Жидкие лечебные составы для внутривенного введения, содержащие декстрозу и инсулин |